COLLEGIUM PHARMACEUTICAL, INC: Invesco Ltd. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Invesco Ltd. filed an amended Schedule 13G with the SEC (accession 0000914208-26-000400) updating its beneficial ownership stake in Collegium Pharmaceutical, Inc. The filing signals a change in the asset manager's position in the specialty pharmaceutical company, though the amended disclosure did not specify the revised share count or percentage in the headline. The update matters because 13G amendments alert investors to shifts in institutional ownership that can influence Collegium's shareholder base and governance dynamics. Investors will watch for the filing's detail on Invesco's exact holdings and any further 13G or 13D activity from other large holders.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Collegium Pharmaceutical, Inc., Invesco Ltd.